Terms: = Lung cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
2922 results:
1. The later-line efficacy and safety of immune checkpoint inhibitors plus anlotinib in EGFR-mutant patients with EGFR-TKI-resistant NSCLC: a single-center retrospective study.
Yin X; Liu X; Ren F; Meng X
Cancer Immunol Immunother; 2024 May; 73(7):134. PubMed ID: 38758372
[TBL] [Abstract] [Full Text] [Related]
2. Overexpression of wild-type HRAS drives non-alcoholic steatohepatitis to hepatocellular carcinoma in mice.
Ling C; Liu SS; Wang YY; Huo GT; Yang YW; Xu N; Wang H; Wu Y; Miao YF; Fu R; Zhao YW; Fan CF
Zool Res; 2024 May; 45(3):551-566. PubMed ID: 38757223
[TBL] [Abstract] [Full Text] [Related]
3. Case report: Sintilimab combined with anlotinib as neoadjuvant chemotherapy for metastatic bone tumor resection in patients with PSC.
Bao Z; Yu X; Zheng K; Zhai K; Cui H; Xu M
Front Immunol; 2024; 15():1372279. PubMed ID: 38756778
[TBL] [Abstract] [Full Text] [Related]
4. Construction of a prognostic model for extensive-stage small cell lung cancer patients undergoing immune therapy in northernmost China and prediction of treatment efficacy based on response status at different time points.
Dang J; Xu G; Guo G; Zhang H; Shang L
J Cancer Res Clin Oncol; 2024 May; 150(5):255. PubMed ID: 38750370
[TBL] [Abstract] [Full Text] [Related]
5. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of pd-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
Sui P; Liu X; Zhong C; Sha Z
Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
[TBL] [Abstract] [Full Text] [Related]
6. Exploring the efficacy and molecular mechanism of Danhong injection comprehensively in the treatment of idiopathic pulmonary fibrosis by combining meta-analysis, network pharmacology, and molecular docking methods.
Wu X; Li W; Luo Z; Chen Y
Medicine (Baltimore); 2024 May; 103(19):e38133. PubMed ID: 38728523
[TBL] [Abstract] [Full Text] [Related]
7. Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Ren S; Xiong A; Yu J; Wang X; Han B; Pan Y; Zhao J; Cheng Y; Hu S; Liu T; Li Y; Cheng Y; Feng J; Yi S; Gu S; Gao S; Luo Y; Liu Y; Liu C; Duan H; Wang S; Yang X; Fan J; Zhou C
Cancer Immunol Immunother; 2024 May; 73(7):124. PubMed ID: 38727837
[TBL] [Abstract] [Full Text] [Related]
8. Immune checkpoint inhibitor associated diarrhoea.
Al-Hussainy A; Adams J; Simmons J; Kennedy J
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719255
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy and safety of pd-1/PD-L1 inhibitors in elderly patients with advanced non-small cell lung cancer.
Li L; Xu C; Wang W; Zhang Q
Clin Respir J; 2024 May; 18(5):e13763. PubMed ID: 38717297
[TBL] [Abstract] [Full Text] [Related]
10. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with driver-gene negative advanced non-small cell lung cancer.
Wang M; Jing X; Chen F; Lu S; Sun Y
BMC Cancer; 2024 May; 24(1):569. PubMed ID: 38714983
[TBL] [Abstract] [Full Text] [Related]
11. Engineering pd-1-targeted small protein variants for in vitro diagnostics and in vivo PET imaging.
Mierzwicka JM; Petroková H; Kafková LR; Kosztyu P; Černý J; Kuchař M; Petřík M; Bendová K; Krasulová K; Groza Y; Vaňková L; Bharadwaj S; Panova N; Křupka M; Škarda J; Raška M; Malý P
J Transl Med; 2024 May; 22(1):426. PubMed ID: 38711085
[TBL] [Abstract] [Full Text] [Related]
12. A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-pd-1/CTLA-4) in Combination with or without Conventional Second-Line treatment for Patients with Extensive Stage Small Cell lung cancer.
Chen C; Chen M; Bai Y; Li Y; Peng J; Yao B; Feng J; Zhou JG; Ma H
Technol Cancer Res Treat; 2024; 23():15330338241249690. PubMed ID: 38706247
[TBL] [Abstract] [Full Text] [Related]
13. CXCR6-positive circulating mucosal-associated invariant T cells can identify patients with non-small cell lung cancer responding to anti-pd-1 immunotherapy.
Qu J; Wu B; Chen L; Wen Z; Fang L; Zheng J; Shen Q; Heng J; Zhou J; Zhou J
J Exp Clin Cancer Res; 2024 May; 43(1):134. PubMed ID: 38698468
[TBL] [Abstract] [Full Text] [Related]
14. Local therapy combined with anti-pd-1 immunotherapy for advanced lung adenocarcinoma: A case report.
Wu N; Yang X; Zhai Y; Lu W
J Cancer Res Ther; 2024 Apr; 20(2):739-744. PubMed ID: 38687948
[TBL] [Abstract] [Full Text] [Related]
15. Outcomes, responses, and prognostic analyses of intrathecal combined treatment for leptomeningeal metastasis from lung adenocarcinoma.
Huang S; Kang X; Wang C; Zhang W; Jiang J; Kang Z; Yang S; Chen J; Chen F; Li W
J Cancer Res Ther; 2024 Apr; 20(2):658-664. PubMed ID: 38687937
[TBL] [Abstract] [Full Text] [Related]
16. Prediction of Responsiveness to PD-L1/pd-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract] [Full Text] [Related]
17. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell lung cancer Treated with pd-1/PD-L1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract] [Full Text] [Related]
18. Evolving insights into the improvement of adoptive T-cell immunotherapy through pd-1/PD-L1 blockade in the clinical spectrum of lung cancer.
Li Y; Sharma A; Schmidt-Wolf IGH
Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
[TBL] [Abstract] [Full Text] [Related]
19. Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
Han R; Guo H; Shi J; Zhao S; Jia Y; Liu X; Liu Y; Cheng L; Zhao C; Li X; Zhou C
BMC Med; 2024 Apr; 22(1):174. PubMed ID: 38658988
[TBL] [Abstract] [Full Text] [Related]
20. Peripheral CD4
Yang X; Li Q; Zeng T
Front Immunol; 2024; 15():1364507. PubMed ID: 38650951
[TBL] [Abstract] [Full Text] [Related]
[Next]